Dexpramipexole Therapy for Eosinophilic COPD Exacerbation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for eosinophilic COPD, including eosinophil-lowering agents like benralizumab and mepolizumab, have failed to demonstrate consistent clinical benefits in reducing exacerbations and improving lung function, highlighting a need for novel therapies that can effectively manage eosinophilic COPD.
Innovation Solution
Oral administration of dexpramipexole or its pharmaceutically acceptable salts, targeting eosinophil hematopoiesis in the bone marrow, to reduce eosinophil counts and improve lung function in patients with eosinophilic COPD.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If eosinophil-lowering agents (benralizumab, mepolizumab) are administered to reduce eosinophil counts, then eosinophil depletion is achieved, but consistent clinical benefits in reducing exacerbations and improving lung function are not demonstrated
Solution Approach 1:
The patent extracts and targets the specific biological pathway of eosinophil hematopoiesis in the bone marrow using dexpramipexole, rather than simply depleting circulating eosinophils. This approach addresses the root production mechanism, potentially providing more reliable and sustained clinical benefits by preventing eosinophil generation at its source in the bone marrow.
2Object-affected harmful factors
If inhaled triple therapy is administered to treat COPD symptoms, then symptom reduction is achieved, but 30-40% of patients continue to experience symptoms and moderate or severe exacerbations
Solution Approach 1:
The patent introduces dexpramipexole as an intermediary agent that targets the underlying eosinophilic inflammation pathway. By acting on the bone marrow to inhibit eosinophil production, this mediator addresses the root inflammatory mechanism that drives exacerbations, providing an additional therapeutic mechanism that complements existing bronchodilator and corticosteroid therapies.
3Quantity of substance
If eosinophil depletion is achieved through current agents, then eosinophil counts are reduced, but lung function improvement and exacerbation reduction are not consistently observed
Solution Approach 1:
The patent employs preliminary action by targeting eosinophil production at the bone marrow level before eosinophils can migrate to the lungs and cause inflammation. Dexpramipexole preemptively inhibits eosinophil hematopoiesis, preventing the inflammatory cascade before it begins, which may lead to more consistent improvements in lung function and reduction in exacerbations.
Data Source
AI summary
The present disclosure provides a method of treating eosinophilic COPD and/or eosinophilic inflammatory responses of eosinophilic COPD in a subject in need thereof. The method comprises orally administering to the subject a therapeutically effective amount of dexpramipexole, or a pharmaceutically acceptable salt thereof. The treating eosinophilic COPD can comprise reducing the rate of COPD exacerbation, reducing a mucus plug score, reducing the rate of hospitalizations due to exacerbations, reducing the rate of oral/parenteral steroid and/or antibiotic use for treatment of COPD, changing the level of one or more biomarkers associated with eosinophilic chronic obstructive pulmonary disorder (COPD), lung function decline, or any combination thereof.